SPP1 and melanoma: We report here for the first time a pilot study examining the potential prognostic utility of plasma osteopontin in early-stage disease patients (AJCC I to III) analysing the effect on risk of death from melanoma or from any cause and taking into account factors already known to be of prognostic value.